Daniel Antonio Perez - 12 Feb 2026 Form 4 Insider Report for Hinge Health, Inc. (HNGE)

Role
CEO & Co-Founder, Director, 10%+ Owner
Signature
/s/ James Budge, Attorney-in-Fact
Issuer symbol
HNGE
Transactions as of
12 Feb 2026
Net transactions value
-$6,710,516
Form type
4
Filing time
13 Feb 2026, 16:34:15 UTC
Previous filing
06 Jan 2026
Next filing
18 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Perez Daniel Antonio CEO & Co-Founder, Director, 10%+ Owner C/O HINGE HEALTH, INC., 455 MARKET STREET, SUITE 700, SAN FRANCISCO /s/ James Budge, Attorney-in-Fact 13 Feb 2026 0002063236

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HNGE Class A Common Stock Conversion of derivative security $0 +166,665 $0.000000 166,665 12 Feb 2026 Direct
transaction HNGE Class A Common Stock Sale $6,710,516 -166,665 -100% $40.26 0 12 Feb 2026 Direct F1, F2
holding HNGE Class A Common Stock 35,470 12 Feb 2026 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HNGE Class B Common Stock Conversion of derivative security $0 -166,665 -1.7% $0.000000 9,488,845 12 Feb 2026 Class A Common Stock 166,665 Direct F3, F4
holding HNGE Class B Common Stock 515,705 12 Feb 2026 Class A Common Stock 515,705 By Spouse F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2025.
F2 Represents the weighted average sale price. The lowest price at which shares were sold was $40.00 and the highest price at which shares were sold was $40.88. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3 Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.
F4 Excludes 4,721,252 performance stock units held by the Reporting Person.